Quantum BioPharma's Lucid-MS Offers New Hope in Multiple Sclerosis Treatment

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that it is featured in a BioMedWire editorial examining the need for new approaches to treating multiple sclerosis (MS), a progressive neurological disease affecting more than 2.9 million people worldwide. The editorial, titled "The Quest to Repair What Multiple Sclerosis Takes Away", highlights the limitations of current therapies, which can slow disease progression but cannot stop it completely.

The editorial discusses Quantum BioPharma's development of Lucid-MS, a patented, first-in-class drug candidate designed to directly target the myelin sheath damaged by MS. The company said the potential therapy is preparing to advance into Phase 2 clinical trials as it pursues a novel approach to treating the disease. Unlike existing treatments that primarily manage symptoms or reduce relapse rates, Lucid-MS aims to prevent and reverse myelin degradation, the underlying mechanism of MS, based on promising preclinical models.

This announcement matters because MS is a debilitating condition with no cure, and current disease-modifying therapies (DMTs) only slow progression. The introduction of a therapy that could potentially repair damaged myelin represents a paradigm shift in MS treatment. If successful, Lucid-MS could offer new hope to millions of patients who experience progressive disability despite existing treatments.

The implications extend beyond MS. Quantum BioPharma's approach to targeting myelin repair could inform treatments for other neurodegenerative conditions characterized by demyelination, such as neuromyelitis optica or certain forms of leukodystrophy. The company's pipeline includes drug candidates for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders.

Quantum BioPharma also holds a stake in Unbuzzd Wellness Inc., which markets UNBUZZD™, an over-the-counter product for alcohol misuse. The company retains a 19.84% ownership in Unbuzzd and receives royalty payments from sales, providing a potential revenue stream while it advances its pharmaceutical pipeline.

For investors and the medical community, the progress of Lucid-MS into Phase 2 trials is a key milestone. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. The full press release can be viewed at https://ibn.fm/WikKX.